Search Results

You are looking at 1 - 10 of 153 items for :

  • "mechanical thrombectomy" x
Clear All
Restricted access

Chirag G. Patil, Elisa F. Long and Maarten G. Lansberg

E ndovascular mechanical thrombectomy for acute ischemic stroke is being increasingly performed by neurosurgeons and neurointerventionalists. Mechanical thrombectomy devices reopen large cerebral vessels and represent an alternative treatment to the standard medical therapy with antiplatelet agents in patients with large-vessel ischemic stroke who are not eligible for thrombolytic therapy, or in whom thrombolytic therapy has failed. The Merci retriever system (Concentric Medical) and more recently, the Penumbra system (Penumbra Inc.) have been granted 510

Full access

Rafael A. Vega, Julie L. Chan, Tony I. Anene-Maidoh, Margaret M. Grimes and John F. Reavey-Cantwell

cardiovascular complications. 5 Cardiac myxoma is the most common primary heart tumor and is a benign neoplasm of endocardial origin. The location is usually in the left atrium. Atrial myxomas can be associated with a syncopal episode or sudden death as well as embolization resulting from tumor dislodgment or thrombus formation that can lead to AIS. 12 These lesions usually have an insidious presentation and the diagnosis is rarely known before or at the onset of stroke. We report an unusual case in which mechanical thrombectomy was used in the successful treatment of AIS

Restricted access

Bing Zhou, Xiao-Chuan Wang, Jun-Yi Xiang, Ming-Zhao Zhang, Bo Li, Hai-Bo Jiang and Xiao-Dong Lu

P ediatric acute ischemic stroke (AIS) is relatively rare compared to adult AIS, but it still plays an important role in pediatric death and disability. 6 , 11 With improvement in thrombectomy apparatus, the application of mechanical thrombectomy is increasingly used in adult AIS and shows good curative effect. However, because of the data scarcity and different pathogenesis in adults, it remains controversial whether mechanical thrombectomy can be used in pediatric AIS. 7 , 14 The purpose of this study was to analyze the safety and effectiveness of mechanical

Restricted access

Carrie E. Andrews, Nikolaos Mouchtouris, Evan M. Fitchett, Fadi Al Saiegh, Michael J. Lang, Victor M. Romo, Nabeel Herial, Pascal Jabbour, Stavropoula I. Tjoumakaris, Robert H. Rosenwasser and M. Reid Gooch

functional outcome at discharge (p = 0.078) ( Table 3 ). FIG. 1. Clinical outcomes after mechanical thrombectomy. HAC = hospital-acquired condition. Figure is available in color online only. TABLE 2. Patient outcomes Age Group <80 Yrs (n = 303) 80–89 Yrs (n = 86) ≥90 Yrs (n = 14) p Value TICI grade 2B–3 264 (87.1%) 73 (84.9%) 14 (100%) 0.627 Favorable outcome (mRS score 0–2) 105 (34.7%) 16 (18.6%) 4 (28.6%) 0.019 Hemorrhagic conversion (grade 4) 33 (10.9%) 6 (7.0%) 1 (7.7%) 0.31 Inpatient mortality 36 (11.8%) 7 (8.1%) 1 (7.1%) 0.292 HACs  PNA 50 (16.5%) 11 (12.8%) 2 (14

Restricted access

Carrie E. Andrews, Nikolaos Mouchtouris, Evan M. Fitchett, Fadi Al Saiegh, Michael J. Lang, Victor M. Romo, Nabeel Herial, Pascal Jabbour, Stavropoula I. Tjoumakaris, Robert H. Rosenwasser and M. Reid Gooch

functional outcome at discharge (p = 0.078) ( Table 3 ). FIG. 1. Clinical outcomes after mechanical thrombectomy. HAC = hospital-acquired condition. Figure is available in color online only. TABLE 2. Patient outcomes Age Group <80 Yrs (n = 303) 80–89 Yrs (n = 86) ≥90 Yrs (n = 14) p Value TICI grade 2B–3 264 (87.1%) 73 (84.9%) 14 (100%) 0.627 Favorable outcome (mRS score 0–2) 105 (34.7%) 16 (18.6%) 4 (28.6%) 0.019 Hemorrhagic conversion (grade 4) 33 (10.9%) 6 (7.0%) 1 (7.7%) 0.31 Inpatient mortality 36 (11.8%) 7 (8.1%) 1 (7.1%) 0.292 HACs  PNA 50 (16.5%) 11 (12.8%) 2 (14

Restricted access

Nikolaos Mouchtouris, Fadi Al Saiegh, Evan Fitchett, Carrie E. Andrews, Michael J. Lang, Ritam Ghosh, Richard F. Schmidt, Nohra Chalouhi, Guilherme Barros, Hekmat Zarzour, Victor Romo, Nabeel Herial, Pascal Jabbour, Stavropoula I. Tjoumakaris, Robert H. Rosenwasser and M. Reid Gooch

Medical, Inc.), not only had improved neurological recovery compared with the medical therapy group, but also had a similar adverse event rate with a limited number of complications (symptomatic intracranial hemorrhage in 6% of patients and embolization in different territory in 4% of patients). 17 While these trials demonstrated the superiority and safety of MT, each trial included a different group of neurointerventionists, and only one device was used per trial. 5 , 20 Our study offers a unique insight into our real-life experience with mechanical thrombectomy by

Restricted access

Kartik Bhatia, Hans Kortman, Christopher Blair, Geoffrey Parker, David Brunacci, Timothy Ang, John Worthington, Prakash Muthusami, Hazem Shoirah, J Mocco and Timo Krings

S ince 2015, the evidence demonstrating the benefit of mechanical thrombectomy (MT) in adults with acute ischemic stroke due to large vessel occlusion has been overwhelming. 21 , 44 In contrast, the role of MT in the pediatric stroke population is still unclear. There are no published randomized controlled trials, case-control studies, or prospective registries. There are multiple reasons for this limited evidence, including the purposeful exclusion of pediatric patients from the major trials as well as the paucity of pediatric acute stroke cases in which

Restricted access

Shaarada Srivatsa, Yifei Duan, John P. Sheppard, Shivani Pahwa, Jonathan Pace, Xiaofei Zhou and Nicholas C. Bambakidis

A cute ischemic stroke is a leading cause of morbidity and mortality in the United States. The efficacy of endovascular mechanical thrombectomy over medical care in select patients with acute ischemic stroke caused by large-vessel occlusion in the anterior circulation has been confirmed. 4 , 10 However, for this technique to be optimally effective, fast and complete recanalization is of paramount importance. 17 First-pass recanalization only occurs in approximately 1 in 4 patients who undergo mechanical thrombectomy, and additional retrieval attempts in the

Free access

Robin M. Babadjouni, Brian P. Walcott, Qinghai Liu, Matthew S. Tenser, Arun P. Amar and William J. Mack

T o date, few effective therapies exist for treatment of acute ischemic stroke (AIS). 2 , 3 , 45 , 74 , 75 In select individuals, intravenous tissue plasminogen activator (tPA) improves outcomes when administered within 4.5 hours of symptom onset. 37 Limitations of intravenous thrombolysis have led to the development of alternative revascularization and reperfusion strategies. 11 , 77 , 78 The 2015 endovascular stroke trials demonstrate that the prompt use of new-generation mechanical thrombectomy devices, particularly stent retrievers, significantly

Restricted access

Lakshmi Leishangthem and Sudhakar R. Satti

S tent retrievers are the newest FDA-approved devices specifically designed for mechanical thrombectomy in patients with acute ischemic stroke. Clinical experience with these new devices is limited. We present here what is to the best of our knowledge the first reported case of an intracranial hemorrhage due to vascular trauma caused during withdrawal of a stent retriever device, Trevo ProVue (Stryker Neurovascular). The risk of endovascular trauma during device removal has not been previously described and the frequency of such injuries may be greater